Viral Gastroenteritis Market Size, Share, By Type (Rotavirus and Norovirus), By Drugs (Antacids, Antibiotics, Laxatives and Antimobility Agents), By Diagnosis, (Rapid Stool Test and Physical Examination), By End-Use (Hospital, Diagnostic Centers, Clinics and Others), and By Region - Market Trends, Analysis, And Forecast Till 2034

Viral Gastroenteritis Market was valued at USD 6.8 Billion in 2024 and is projected to grow at a CAGR of 4.6% to reach USD 10.2 Billion by 2034.

Viral Gastroenteritis Market is a common gastrointestinal illness that affects people all over the world. The lining of the stomach, small intestine, and large intestine is inflamed by viral gastroenteritis, also known as stomach flu. Viral gastroenteritis is caused by a variety of viruses. Norovirus, rotavirus, astrovirus, and enteric adenovirus are among the viruses that cause viral gastroenteritis. The most common viruses that cause this illness are norovirus and rotavirus. Direct contact with the patient, as well as infected water or food, are both ways to spread this disease. The key goal of treatment is to rehydrate the patient by consuming enough water or fluids. Vomiting, nausea, cramps, and muscle ache are all symptoms of viral gastroenteritis.

               For More Report Details, Download Free Sample PDF

Growth in business operations by emerging and small sized players

The market is growing due to the rising prevalence of gastrointestinal disease around the world, and the research and development in gastroenterology. In addition, rising concerns about the disease's spread among children and the urgent need to treat viral gastroenteritis are driving market development. Manufacturers' introduction of novel products and an expanding patient pool are expected to drive the gastrointestinal infection testing market forward during the forecast period. In addition, there is a growing need for new medications to treat the disease.

The Viral Gastroenteritis market is segmented based on type, drugs, diagnosis, end-use, and region.

On the basis of type, the viral gastroenteritis market is segmented into Rotavirus and Norovirus. Based on drugs, the target market is segmented into Antacids, Antibiotics, Laxatives and Antimobility agents. On the basis of diagnosis, the market is segmented into Rapid stool tests and Physical examination. On the basis of end-use, the target market is segmented into Hospitals, Diagnostic centers, Clinics and Others.

Regional Insights:

On region the Viral Gastroenteritis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to lead the market in the upcoming forecast era. This is mainly attributed because of the increasing prevalence of viral gastroenteritis in the U.S., especially among children. The second-largest market for viral gastroenteritis is Europe. Rotavirus is the most common cause of serious gastroenteritis in children under the age of five years in Asia Pacific. Increased demand for rapid diagnostic tests for gastrointestinal diseases and increased knowledge of available treatment options for viral gastroenteritis are driving the market in Asia Pacific.

Viral Gastroenteritis Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global viral gastroenteritis market report based on type, drugs, diagnosis, end-use, and region.

Viral Gastroenteritis Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the viral gastroenteritis market includes Abbott, Valeant Pharmaceuticals International Inc. Janssen Global Services, LLC, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc., Bayer AG, AstraZeneca and Sanofi.

• In April 2023, Researchers at Washington University School of Medicine in St. Louis came up with a novel method to create a vaccine against norovirus by building on the extremely successful rotavirus vaccines, which targets the rotavirus a different virus that also causes diarrhoea. The novel dual vaccination, which combines the major two viruses that cause diarrhoea, produces antibodies that protect against rotavirus and norovirus infections.

• Abbott
• Valeant Pharmaceuticals International Inc.
• Janssen Global Services LLC
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline Plc.
• Bayer AG
• AstraZeneca
• Sanofi